Editing Novartis (section)

==Corporate structure==
{{Pie chart
| caption= Shareholders of Novartis by country of origin as of December 31, 2022:<ref>{{Cite news |date=2023-06-12 |title=Share Ownership |language=en |work=Novartis |url=https://www.novartis.com/investors/share-data-analysis/share-ownership |access-date=2023-06-12 |archive-date=30 March 2023 |archive-url=https://web.archive.org/web/20230330223648/https://www.novartis.com/investors/share-data-analysis/share-ownership|url-status=live }}</ref> | label1 = Switzerland | value1 = 48.39 | color1 = red | label2 = United Kingdom | value2 = 23.68 | color2 = blue | label3 = United States | value3 = 21.29 | color3 = green | label4 = Other countries | value4 = 6.64 | color4 = yellow}}

Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group and owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group.<ref name=":2">{{Cite web |title=SEC 2010 |url=https://www.sec.gov/Archives/edgar/data/1114448/000104746910000310/a2196017z20-f.htm |access-date=9 January 2020 |archive-date=6 August 2020 |archive-url=https://web.archive.org/web/20200806011642/https://www.sec.gov/Archives/edgar/data/1114448/000104746910000310/a2196017z20-f.htm |url-status=live }}</ref>

Novartis's businesses are divided into two operating divisions: Innovative Medicines and Sandoz (generics).<ref>{{Cite news |last=Roland |first=Denise |title=Novartis Pharmaceuticals Head to Depart Amid Restructuring |url=https://www.wsj.com/articles/novartis-to-split-pharmaceuticals-division-into-two-1463506092 |access-date=2020-01-09 |newspaper=Wall Street Journal |date=17 May 2016 |language=en-US |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805221151/https://www.wsj.com/articles/novartis-to-split-pharmaceuticals-division-into-two-1463506092 |url-status=live }}</ref> The eye-care division [[Alcon]] was spun off into an independent company in April 2019.<ref>{{Cite news |date=2019-04-03 |title=Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI |language=en |work=Reuters |url=https://www.reuters.com/article/us-alcon-spinoff-novartis-idUSKCN1RF10X |access-date=2023-06-12 |archive-date=12 June 2023 |archive-url=https://web.archive.org/web/20230612062233/https://www.reuters.com/article/us-alcon-spinoff-novartis-idUSKCN1RF10X |url-status=live }}</ref><ref>{{Cite web |title=Alcon to Officially Spin out From Novartis on April 9 |url=https://www.biospace.com/article/alcon-to-begin-trading-on-nyse-on-april-9/ |access-date=2020-01-09 |website=BioSpace |date=22 March 2019 |language=en-US |archive-date=6 August 2020 |archive-url=https://web.archive.org/web/20200806004648/https://www.biospace.com/article/alcon-to-begin-trading-on-nyse-on-april-9/ |url-status=live }}</ref><ref>{{Cite web |title=Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off |url=https://www.novartis.com/news/media-releases/novartis-continues-transformation-leading-medicines-company-completion-alcon-spin |access-date=2023-06-12 |website=Novartis |language=en |archive-date=12 June 2023 |archive-url=https://web.archive.org/web/20230612062218/https://www.novartis.com/news/media-releases/novartis-continues-transformation-leading-medicines-company-completion-alcon-spin |url-status=live }}</ref><ref>{{Cite web |title=Alcon Debuts as Independent, Publicly Traded Company |url=https://investor.alcon.com/news-and-events/press-releases/news-details/2019/Alcon-Debuts-as-Independent-Publicly-Traded-Company/default.aspx |access-date=2023-06-12 |website=investor.alcon.com |language=en-US |archive-date=12 June 2023 |archive-url=https://web.archive.org/web/20230612062237/https://investor.alcon.com/news-and-events/press-releases/news-details/2019/Alcon-Debuts-as-Independent-Publicly-Traded-Company/default.aspx |url-status=live }}</ref> In August 2022, Novartis announced plans to spin off Sandoz as part of restructuring. The spin-off was completed in October 2023.<ref name="spinoff-complete">{{Cite web |last1=Veyet |first1=Tristan |last2=Illien |first2=Noele |date=2023-10-04 |title=Novartis completes Sandoz spinoff |url=https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-completes-sandoz-spinoff-2023-10-04/ |access-date=2023-10-04 |work=Reuters |language=en |archive-date=4 October 2023 |archive-url=https://web.archive.org/web/20231004123809/https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-completes-sandoz-spinoff-2023-10-04/ |url-status=live }}</ref><ref>{{Cite news |last=Grover |first=Natalie |date=2022-08-25 |title=Novartis to spin off generics business Sandoz next year |language=en |work=Reuters |url=https://www.reuters.com/markets/deals/novartis-spin-off-sandoz-list-it-zurich-2022-08-25/ |access-date=2023-06-12 |archive-date=12 June 2023 |archive-url=https://web.archive.org/web/20230612062233/https://www.reuters.com/markets/deals/novartis-spin-off-sandoz-list-it-zurich-2022-08-25/ |url-status=live }}</ref><ref name=sandoz-ft>{{cite news |url=https://www.ft.com/content/00a14f97-fa94-4d0b-a17e-9d7e5b876f4b |archive-url=https://ghostarchive.org/archive/20221210/https://www.ft.com/content/00a14f97-fa94-4d0b-a17e-9d7e5b876f4b |archive-date=10 December 2022 |url-access=subscription |url-status=live |title=Novartis to spin off generic drugs unit Sandoz |date=25 August 2022 |work=[[Financial Times]] |first1=Donato Paolo |last1=Mancini |first2=Oliver |last2=Telling}}</ref>

The Innovative Medicines business is made up of two commercial units: Innovative Medicines International and Innovative Medicines US.<ref>{{Cite web |last=Keystone-SDA/jdp |date=2022-09-22 |title=Novartis sets sights on high-value medicines and US market |url=https://www.swissinfo.ch/eng/business/novartis-sets-sights-on-high-value-medicines-and-us-market/47920840 |access-date=2023-06-12 |website=SWI swissinfo.ch |language=en}}</ref><ref>{{Cite web |title=Innovative Medicines |url=https://www.novartis.com/about/innovative-medicines |access-date=2023-06-12 |website=Novartis |language=en |archive-date=12 June 2023 |archive-url=https://web.archive.org/web/20230612062225/https://www.novartis.com/about/innovative-medicines |url-status=live }}</ref> The two business units combine the pharmaceutical and oncology divisions and commercially focus on global and US market respectively.<ref>{{Cite web |date=2022-04-04 |title=Novartis restructures organisation to support growth and innovation |url=https://www.pmlive.com/pharma_news/novartis_restructures_organisation_to_support_growth_and_innovation_1389761 |access-date=2023-06-12 |website=PMLive |language=en |archive-date=12 June 2023 |archive-url=https://web.archive.org/web/20230612062226/https://www.pmlive.com/pharma_news/novartis_restructures_organisation_to_support_growth_and_innovation_1389761 |url-status=live }}</ref><ref>{{Cite web |title=JPM23: Novartis takes sweeping approach to 'US-first' mindset, exec says |date=17 January 2023 |url=https://www.fiercepharma.com/pharma/novartis-takes-comprehensive-approach-us-first-mindset-us-chief-bulto |access-date=12 June 2023 |archive-date=12 June 2023 |archive-url=https://web.archive.org/web/20230612062219/https://www.fiercepharma.com/pharma/novartis-takes-comprehensive-approach-us-first-mindset-us-chief-bulto |url-status=live }}</ref>

Novartis operates directly through subsidiaries, each of which fall under one of the divisions, and that Novartis categorizes as fulfilling one or more of the following functions: Holding/Finance, Sales, Production, and Research<ref name=":2" /><ref name="AR2012">{{Cite web |title=Novartis Annual Report 2012 |url=http://www.novartis.com/downloads/investors/reports/novartis-annual-report-2012-en.pdf |archive-url=https://web.archive.org/web/20130228120424/http://www.novartis.com/downloads/investors/reports/novartis-annual-report-2012-en.pdf |archive-date=2013-02-28 |access-date=6 February 2018 |website=Novartis}}</ref>{{rp|251–253}}

Novartis AG also held 33.3 percent of the shares of [[Hoffmann-La Roche|Roche]] until 2022, however it did not exercise control over Roche.<ref>{{Cite web |title=Novartis AG to Hold On to Its 33% Stake in Roche—For Now |url=https://www.biospace.com/article/novartis-ag-to-hold-on-to-its-33-percent-stake-in-roche-for-now-/ |access-date=2020-01-10 |website=BioSpace |date=12 October 2017 |language=en-US |archive-date=1 November 2020 |archive-url=https://web.archive.org/web/20201101033841/https://www.biospace.com/article/novartis-ag-to-hold-on-to-its-33-percent-stake-in-roche-for-now-/ |url-status=live }}</ref> Novartis also has two significant license agreements with [[Genentech]], a Roche subsidiary.<ref>{{Cite web |title=Avastin vs Lucentis |url=https://www.beuc.eu/publications/beuc-x-2014-012_ipa_avastin_vs_lucentis-letter_to_v-p_almunia.pdf |access-date=29 January 2021 |archive-date=6 August 2020 |archive-url=https://web.archive.org/web/20200806005225/https://www.beuc.eu/publications/beuc-x-2014-012_ipa_avastin_vs_lucentis-letter_to_v-p_almunia.pdf |url-status=live }}</ref> One agreement is for [[Lucentis]];<ref>{{Cite press release |last=AG |first=Novartis Pharma |date=2003-06-25 |title=Novartis Ophthalmics and Genentech announce development and commercialization agreement for age-related macular degeneration treatment, Lucentis(TM) |url=https://www.globenewswire.com/news-release/2003/06/25/1839492/0/en/Novartis-Ophthalmics-and-Genentech-announce-development-and-commercialization-agreement-for-age-related-macular-degeneration-treatment-Lucentis-TM.html |access-date=2023-06-12 |website=GlobeNewswire News Room |language=en}}</ref> the other is for [[Xolair]].<ref>{{Cite web |title=Press release issued jointly by Genentech, Inc. and Tanox Inc. |url=https://www.sec.gov/Archives/edgar/data/318771/000119312506237338/dex991.htm |access-date=2023-06-12 |website=www.sec.gov |archive-date=12 June 2023 |archive-url=https://web.archive.org/web/20230612062218/https://www.sec.gov/Archives/edgar/data/318771/000119312506237338/dex991.htm |url-status=live }}</ref><ref name="AR2012" />{{rp|239}}

In 2014, Novartis established a center in [[Hyderabad]], India, in order to offshore several of its R&D, clinical development, medical writing and administrative functions.<ref>{{Cite web |title=Novartis slashing thousands more jobs in global reorganization, shifting many to India |url=http://www.fiercepharma.com/story/nzz-novartis-will-cut-or-move-4000-jobs-many-india/2014-02-02 |website=FiercePharma |date=2 February 2014 |access-date=4 February 2015 |archive-date=2 August 2019 |archive-url=https://web.archive.org/web/20190802165715/https://www.fiercepharma.com/regulatory/novartis-slashing-thousands-more-jobs-global-reorganization-shifting-many-to-india |url-status=live }}</ref> The center supports the drug major's operations in the pharmaceuticals (Novartis), eye care (Alcon), and generic drugs segments (Sandoz).<ref>{{Cite news |last=Datta |first=P. T. Jyothi |date=2015-12-18 |title=Novartis consolidates global services operations at Hyderabad centre |work=The Hindu BusinessLine |url=https://www.thehindubusinessline.com/companies/novartis-consolidates-global-services-operations-at-hyderabad-centre/article8005067.ece |access-date=2020-02-06 |archive-date=8 November 2020 |archive-url=https://web.archive.org/web/20201108102041/http://www.thehindubusinessline.com/companies/novartis-consolidates-global-services-operations-at-hyderabad-centre/article8005067.ece |url-status=live }}</ref>